ArticleDiscover oncology2025
A comprehensive analysis through Mendelian randomization of immunological markers and sphingolipid metabolism.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer pathogenesis involves complex interactions between immune system components and metabolic pathways. However, the causal relationships between these factors remain unclear. This study aimed to employ Mendelian randomization (MR) analysis to establish causal links between immunological markers, metabolic factors, and lung cancer development, while integrating multi-omics data for comprehensive molecular characterization.
methodsWe conducted a two-sample MR analysis of 731 immunological features and 1,400 metabolites using inverse-variance weighted methodology. The analysis was supplemented with single-cell expression profiling, functional enrichment analysis, and machine learning approaches. Multiple MR methodologies, including MR-Egger and heterogeneity testing via Cochran's Q statistic, were employed to validate findings. We specifically investigated the mediating role of sphingomyelin in the relationship between T cell %lymphocyte levels and lung cancer risk.
resultsMR analysis identified 25 blood cell phenotypes significantly linked to lung cancer susceptibility, with memory antigen-presenting cells showing notable risk association (OR = 1.0763, 95%CI: 1.0147-1.1417, P = 0.0145). Seventy-six metabolites demonstrated causal influences on lung cancer pathogenesis, particularly within sphingolipid metabolism pathways. Single-cell profiling revealed significant differential expression of six genes (APCDD1L, CNTNAP4, GNG13, KIRREL2, LINC00628, and LIPK) between normal and tumor tissues. Machine learning models constructed from these findings demonstrated robust predictive performance in both TCGA and GEO datasets.
conclusionsThrough rigorous MR analysis, this study establishes causal relationships between specific immune markers, metabolic pathways, and lung cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.